News and Announcements
CEO Dr James Garner speaks about GDC-0084 data with Proactive Investors
- Published November 25, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Our CEO, Dr James Garner discussed the significance of the interim efficacy data from Kazia’s phase II trial of GDC-0084 in glioblastoma in an interview with Proactive Investors.
In the interview, Dr Garner talks about:
- How the median progression-free survival rate of 8.3 months strongly suggests that GDC-0084 is delaying the progression of glioblastoma in the patients treated
- How the data signals that GDC-0084 may be extending life expectancy for the patients treated
- How the data compares to the existing treatment option for glioblastoma, temozolomide
- The next steps for the phase II study and Kazia more generally
Watch the video interview here
About KaziaTherapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
Dubai: The Unsung Bridge for Global Tech Investment and Market Access
In the bustling world of global tech and investment, Dubai is often seen through the lens of its impressive skyline and rapid development. However, beneath the gleaming facade lies a sophisticated ecosystem designed to be a crucial bridge for founders seeking capital and market access, and for investors looking to tap into burgeoning opportunities across […]
Beyond Strategy: Why Your Network Will Define Your Business Exit
Beyond operational readiness, a strong, purpose-built network is crucial for a successful business exit. Learn how an “exit ecosystem” of advisors, capital partners, and fellow founders can define the outcome of your most significant transaction.
Australia’s Trillion-Dollar Defence Tech Boom: A Call to Action for Founders
The global defence technology landscape is no longer a niche for the select few. For Australian founders, it represents a monumental, yet frequently underestimated, investment opportunity. Fuelled by escalating geopolitical tensions and a fundamental re-prioritisation of global spending, this sector is experiencing an unprecedented tailwind. According to Steve Baxter, Lead Investor at Beaten Zone Venture […]
Backed By Leading Investment Groups and Family Offices
